Rothschild & Co Asset Management US’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | $6.82M | Sell |
|
|||||
|
2022
Q3 | $6.84M | Sell |
|
|||||
|
2022
Q2 | $7.21M | Sell |
|
|||||
|
2022
Q1 | $7.36M | Sell |
|
|||||
|
2021
Q4 | $8.63M | Buy |
|
|||||
|
2021
Q3 | $8.51M | Sell |
|
|||||
|
2021
Q2 | $9.31M | Sell |
|
|||||
|
2021
Q1 | $10.4M | Sell |
|
|||||
|
2020
Q4 | $14.8M | Buy |
|
|||||
|
2020
Q3 | $13M | Sell |
|
|||||
|
2020
Q2 | $20M | Sell |
|
|||||
|
2020
Q1 | $18.1M | Sell |
|
|||||
|
2019
Q4 | $24.5M | Sell |
|
|||||
|
2019
Q3 | $21.5M | Buy |
|
|||||
|
2019
Q2 | $17.7M | Buy |
|
|||||
|
2019
Q1 | $13.2M | Buy |
|
|||||
|
2018
Q4 | $6.54M | Buy |
|
|||||
|
2018
Q3 | $8.21M | Buy |
|
|||||
|
2018
Q1 | – | Sell |
|
|||||
|
2017
Q4 | $2.06M | Sell |
|
|||||
|
2017
Q3 | $2.31M | Sell |
|
|||||
|
2017
Q2 | $1.74M | Sell |
|
|||||
|
2017
Q1 | $1.74M | Sell |
|
|||||
|
2016
Q4 | $1.63M | Buy |
|
|||||
|
2016
Q3 | $394K | Buy |
|
|||||
|
2016
Q2 | $353K | Buy |
|
|||||
|
2015
Q3 | – | Sell |
|
|||||
|
2015
Q2 | $239K | Buy |
|